<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231113060043N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-23</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of superior cervical sympathetic ganglion block using radiofrequency in the treatment of tinnitus</public_title>
      <acronym></acronym>
      <scientific_title>The effect of superior cervical sympathetic ganglion block using radiofrequency in the treatment of adult patients with tinnitus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73780</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be included in the study based on a randomly prepared list. This list contains a series of random numbers, each number is assigned to a type of treatment and according to that treatment is done.

1, 4, 1, Group Ganglion Block
    1, 4, 2, Cinnarizine
    1, 4, 3, Cinnarizine
    1, 4, 4, Group Ganglion Block
    2, 4, 1, Group Ganglion Block
    2, 4, 2, Cinnarizine
    2, 4, 3, Group Ganglion Block
    2, 4, 4, Cinnarizine
    3, 4, 1, Cinnarizine
    3, 4, 2, Group Ganglion Block
    3, 4, 3, Group Ganglion Block
    3, 4, 4, Cinnarizine
    4, 4, 1, Group Ganglion Block
    4, 4, 2, Group Ganglion Block
    4, 4, 3, Cinnarizine
    4, 4, 4, Cinnarizine
    5, 4, 1, Cinnarizine
    5, 4, 2, Cinnarizine
    5, 4, 3, Group Ganglion Block
    5, 4, 4, Group Ganglion Block
    6, 4, 1, Cinnarizine
    6, 4, 2, Group Ganglion Block

    6, 4, 3, Cinnarizine
    6, 4, 4, Group Ganglion Block
    7, 4, 1, Group Ganglion Block
    7, 4, 2, Group Ganglion Block
    7, 4, 3, Cinnarizine
    7, 4, 4, Cinnarizine
    8, 4, 1, Cinnarizine
    8, 4, 2, Group Ganglion Block
    8, 4, 3, Cinnarizine
    8, 4, 4, Group Ganglion Block
    9, 4, 1, Cinnarizine
    9, 4, 2, Group Ganglion Block
    9, 4, 3, Cinnarizine
    9, 4, 4, Group Ganglion Block
    10, 4, 1, Group Ganglion Block
    10, 4, 2, Cinnarizine
    10, 4, 3, Cinnarizine
    10, 4, 4, Group Ganglion Block
    11, 4, 1, Cinnarizine
    11, 4, 2, Group Ganglion Block
    11, 4, 3, Group Ganglion Block
    11, 4, 4, Cinnarizine

    12, 4, 1, Group Ganglion Block
    12, 4, 2, Group Ganglion Block
    12, 4, 3, Cinnarizine
    12, 4, 4, Cinnarizine
    13, 4, 1, Group Ganglion Block
    13, 4, 2, Cinnarizine
    13, 4, 3, Group Ganglion Block
    13, 4, 4, Cinnarizine, Blinding description: The person evaluating the improvement of tinnitus after treatment will not be aware of the type of treatment performed on the patient, and blinding will be done in a single blind.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Tinnitus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: There are patients who, after checking the sensory and motor nerves, in order to prevent nerve damage, and after choosing the correct location, which is basically in the roots of c1, c2, c3, They are treated with a block of the superior sympathetic ganglion of the neck using a radiofrequency pulse. Intervention 2: Control group: There are patients who are treated with the drug Cinnarizine 25 twice a day. That is, with an average dose of 50 mg daily, people will be treated with medicine.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Fahimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bo Ali Sina Medical Education Center, Pasdaran Blvd., Mazandaran</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815838477</zip>
        <telephone>+98 11 3334 3015</telephone>
        <email>alifahimi2005@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Daneshian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bo Ali Sina Medical Education Center, Pasdaran Blvd., Mazandaran</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815838477</zip>
        <telephone>+98 11 3334 3014</telephone>
        <email>mdaneshian@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with Tinnitus without response to drug treatment
Patients who have been examined neurologically and do not have neurological problem
People who are over 18 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Taking drugs that cause tinnitus, such as: Aminoglycosides and Loop diuretics
People with known neurological diseases such as MS
Patients with coagulation disorders or the use of anticoagulant drugs
Patients who in addition to tinnitus, have neck injuries, especially in the C2 region, and other neck problems such as cervical spinal canal stenosis.
Lack of patient satisfaction and cooperation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H93.19</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Tinnitus, unspecified ear</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: There are patients who, after checking the sensory and motor nerves, in order to prevent nerve damage, and after choosing the correct location, which is basically in the roots of c1, c2, c3, They are treated with a block of the superior sympathetic ganglion of the neck using a radiofrequency pulse</i_keyword>
      <i_keyword>Control group: There are patients who are treated with the drug Cinnarizine 25 twice a day. That is, with an average dose of 50 mg daily, people will be treated with medicine.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Improvement in tinnitus. Timepoint: One week, one month, 3, 6, 12, 18 and 24 months (within two years) after the procedure. Method of measurement: Patients will rate the degree of improvement of tinnitus using a scoring questionnaire from 0 to 10.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Nausea - vomiting. Timepoint: Immediately after the operation - 3 hours later 6, 12 and 24 hours after the operation - one week later. Method of measurement: Examination and expression by the patient.</sec_outcome>
      <sec_outcome>Bleeding in the operation area. Timepoint: during the operation, 1hour , 6, 12, 24 hours after the operation. Method of measurement: Examination and observation by a doctor.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-06</approval_date>
        <contact_name>Ethics Committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Mazandaran University of Medical Sciences and Health Care Services Building No. 2 , Moalem Square, Sari Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
